#Taiwan #Taipei #University of Tokyo #Anbogen #ABT-301

Collaborative Efforts in Oncology Research

Anbogen Therapeutics Inc., a clinical-stage precision oncology firm, has announced an intriguing collaboration with The University of Tokyo's Laboratory of Veterinary Surgery. The partnership aims to explore the efficacy of ABT-301, a selective Class I histone deacetylase inhibitor (HDACi), across several solid tumor types, including aggressive cancers like osteosarcoma, melanoma, and soft tissue sarcoma. Utilizing veterinary oncology models, the collaboration seeks to accelerate the human clinical indication expansion for ABT-301.

Rationale Behind the Collaboration

The initiative will leverage insights from the extensive expertise at the University in translational oncology, cancer immunotherapy, and genomic medicine. As the research team works under the guidance of professionals such as Lecturer Daiki Kato, Professor Takayuki Nakagawa, and Professor Manabu Mochizuki, they will employ models that closely mirror real-world disease states.

Traditionally, cancer research faces challenges when studying early-stage human clinical developments. The naturally occurring cancers in canines provide a unique window into these processes as they exhibit compelling biological and clinical parallels to human cancers. For instance, canine osteosarcoma has garnered attention as an effective comparative oncology model due to its similarities to human cases. This collaboration aims to exploit these insights to evaluate therapeutic strategies that can be immensely beneficial for human clinical trails.

Goals of the Collaborative Research

The primary focus of this research arrangement is to gather scientific evidence that supports the expansion of clinical indications for ABT-301. By employing The University of Tokyo’s proprietary preclinical models, the collaboration intends to assess ABT-301 both as a standalone treatment and in combination with other therapeutic agents—a strategy aimed at elucidating its mechanisms of action while identifying molecular profiles predictive of positive treatment outcomes.

Dr. John Hsu, the Chairman and CEO of Anbogen Therapeutics, commented, "Comparative oncology provides a robust platform for fostering translational evidence that bridges animal research with human oncology. Our objective is to evaluate ABT-301 in conditions that more accurately reflect real-world disease biology, thereby producing data that can effectively guide clinical development and indication expansion."

The Importance of ABT-301

Currently under evaluation in a Phase I/II trial, ABT-301 is poised as a promising candidate for treating metastatic colorectal cancer in conjunction with anti-PD-1 and anti-VEGF therapies. The molecule is specifically designed to reconfigure the immune landscape of tumors, making them more responsive to immunotherapy.

The backdrop for this development is a successful history of clinical evidence showing significant efficacy in advanced cancers through the synergistic approach of combining HDAC inhibitors with immune checkpoint inhibitors. Such combinations have notably enhanced progression-free survival (PFS) among patients, bolstering confidence in ABT-301's potential applicability across a variety of solid tumors.

Dog Models Resonate with Human Oncology

Research leader Dr. Daiki Kato highlighted the relevance of using canine and feline cancers in this study. He stated, "Naturally occurring cancers in pets evolve within environments similar to those of humans, acquiring intricate immune landscapes that serve as solid models for human diseases. These models can reproduce clinical features that are often challenging to observe in typical preclinical studies."

This partnership symbolizes a strategic blending of concepts, providing a firm basis for optimizing the treatment landscape in oncology. The findings from this collaboration will directly influence future clinical trials, including indication selections and the design of combination regimens.

Conclusion

As both Anbogen Therapeutics and The University of Tokyo embark on this ambitious venture, the cancer research community looks forward to the production of groundbreaking results that could reshape treatment paradigms for difficult-to-treat cancers. With ABT-301 at the forefront, this collaboration not only aims to advance clinical development but also to solidify the foundations of comparative oncology in bridging the gap between animal and human health issues.